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Introduction
Epidemiology
Heart failure (HF) has an incidence of 1 to 2% in the gen-
eral population [1]. Its prevalence increases further 
with age, rising from approximately 2% in individuals 
65–69 years old to >8% in those ≥85 years [2]. The mor-
tality rate of systolic HF is 14% at 1 year and up to 50% at 
5 years, when symptomatic [2–4]. The average duration 
of survival aer one hospitalisation is 2.4 years and 
drops to 0.6 year aer the fourth hospitalisation [5]. 
About 25–40% of patients with congestive HF have a 
preserved ejection fraction and suer from  diastolic 
failure; their mortality is 50% lower than in the case of 
reduced ejection fraction [4].
Heart failure as a perioperative risk factor
HF is known to be a major risk factor in perioperative 
care and is found in 2.5 to 10% of noncardiac surgical 
patients [6–8]. The incidence of severe cardiac events 
aer major noncardiac surgery is between 2 and 8% [6, 
9, 10]. In cardiac surgery, the incidence rises to over 
20% [11]. In vascular surgery, it is 18% in the case of iso-
lated diastolic failure, 23% in the case of asymptomatic 
systolic insuciency and 49% in the case of congestive 
systolic failure [12]. In a retrospective study including 
1 532 HF patients and 1 757 coronary artery disease 
(CAD) patients undergoing major noncardiac surgery, 
the risk-adjusted mortality within 30 days was 11.7% in 
HF, 6.6% in CAD and 6.2% in control patients. The 
risk-adjusted 30-day readmission rate was 20% for HF, 
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14.2% for CAD and 11% for control patients [13]. HF pa-
tients undergoing major noncardiac surgery suered 
substantial morbidity and mortality despite  advances 
in perioperative care, whereas patients with CAD with-
out HF had similar mortality to a more general popula-
tion [10, 13, 14]. It is not only the peri operative cardiac 
risk which is high in HF patients but also the noncar-
diac complication incidence is higher than in patients 
without CAD or HF, as shown recently [14]. In this retro-
spective series, a near doubling of postoperative death 
was reported in HF patients, as well as a 40 to 69% 
 increased risk of sepsis, and pulmonary and renal 
 complications, but not of myocardial in farction. Peri-
operative management may have been focused on 
 preventing myocardial ischaemia at the  expense of 
other organ systems.
Interestingly, the newly published European Society of 
Cardiology (ESC) / European Surgical Association (ESA) 
guidelines on noncardiac surgery dene the perioper-
ative cardiac risk as follows: “cardiac complications can 
arise in patients with documented or asymptomatic is-
chaemic heart disease, le ventricular dysfunction, 
valvular heart disease and arrhythmias, who undergo 
surgical procedures that are associated with prolonged 
haemodynamic and cardiac stress” [15]. We may won-
der why the role of right ventricular failure (RVF) in 
peri operative cardiac risk is so neglected. There is a 
plethora of literature and guidelines on the periopera-
tive management of patients with coronary artery dis-
ease and le ventricular failure (LVF), but until now, 
there is a lack of guidelines on the perioperative man-
agement of the patient with RVF. However, RVF has 
been clearly associated with increased mortality 
among cardiac surgical patients as well as in the 
non-cardiac setting and in the intensive care unit (ICU) 
[16]; it is present in approximately 40% of postcardiot-
omy cardiogenic shock [11, 17, 18].
Risk assessment
Preoperative risk assessment is essential, considering 
the risks of surgery (emergency, type, invasiveness, du-
ration and potential blood loss), and the risks of the 
 patient, considering their personal history (history of 
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ischaemic cardiac disease, HF, cerebrovascular disease, 
insulin-dependent diabetes mellitus and impaired 
 renal function) and their functional capacity (in meta-
bolic equivalents, METs) [19]. Many dierent indices 
have been designed since the Revised Cardiac Risk In-
dex of Lee [20], but their accuracy and concordance are 
limited [21]. According to the 2014 ESC/ESA guidelines, 
patients with established or suspected HF scheduled 
for noncardiac intermediate or high-risk surgery 
should undergo transthoracic echocardiography and/
or assessment of natriuretic peptides, and should be 
therapeutically optimised as necessary, using beta- 
blockers, angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers, mineralocorticoid 
 antagonists and diuretics [15]. In cardiac surgery, indi-
cators of major clinical risk in the perioperative period 
are: unstable coronary syndromes, decompensated HF, 
signicant arrhythmias and severe valvular disease 
[19]. The EuroSCORE II is currently used for periopera-
tive risk assessment in cardiac surgery [22]. 
Denition and diagnosis of heart failure
Denition
HF is a functional and structural impairment of ven-
tricular lling and/or ejection, leading to a failure of 
oxygen and nutrient delivery at a rate in accordance 
with the requirements of the tissues. It should be sub-
divided into le and right ventricular failure as well as 
systolic or diastolic dysfunction. Dia stolic dysfunction 
resulting in depressed lling of the ventricle is mostly 
a disease of the le ventricle. Systolic dysfunction 
 results in poor ventricular ejection and aects both 
ventricles. Whereas diastolic failure may occur with-
out overt systolic failure, the latter is always accompa-
nied by diastolic failure. Basically, ve myocardial 
mechanisms lead to HF: arrhythmias, pressure over-
load, volume overload, coronary disease and primary 
myocardial disease (cardiomyopathy). Clinically, acute 
HF presents frequently as pulmonary oedema, le/
right congestive HF or cardiogenic shock with progres-
sive end-organ malperfusion and possible failure [23]. 
Both the American College of Cardiology Foundation 
(ACCF) / American Heart Association (AHA) stages of 
HF and the New York Heart Association (NYHA) func-
tional classication are useful complementary infor-
mation about the presence and the severity of HF (table 
1) [2]. HF patients commonly suer from comorbidities 
among which the 10 most frequent are: systemic 
 hypertension (84%), ischaemic heart disease (72%), 
 hyperlipidaemia (60%), anaemia (50%), diabetes (46%), 
arthritis (43.5%), chronic kidney disease (42%), chronic 
obstructive pulomonary disease (COPD) (30%), atrial 
 brillation (28.5%) and Alzheimer’s disease / dementia 
(28%) [19]. 
Diagnosis
The diagnosis of acute HF is based on clinical signs, 
echocardiography and cardiac biomarkers. Among the 
clinical signs are: orthopnoea, rales, abdominal dis-
comfort, peripheral oedema, hypotension, tachycar-
dia, oliguria, cyanosis, mottling and disorder of con-
sciousness. Perioperative echocardiography should be 
performed as early as possible and will quickly provide 
information on regional and global ventricular func-
tion, right or le ventricular dysfunction, valvular dys-
function, tamponade and volume status. Whereas an 
increase in troponin level is highly correlated with 
postoperative major adverse cardiac events (MACE), 
the diagnostic role of natriuretic peptides (BNP, NT-
pro-BNP) in the perioperative period remains to be 
demonstrated [24].
Table 1: Comparison of ACCF/AHA stages of HF and NYHA functional classification.
ACCF/AHA stages of HF NYHA functional classification
A At high risk for HF but without structural heart disease 
or symptoms of HF
0
B Structural heart disease but without signs or 
 symptoms of HF
I No limitation of physical activity, ordinary physical activity 
does not cause symptoms of HF
C Structural heart disease with prior or current 
 symptoms of HF
I
II
III
IV
No limitation of physical activity, ordinary physical activity 
does not cause symptoms of HF
Slight limitation of physical activity. Comfortable at rest, 
but  ordinary physical activity results in symptoms of HF
Marked limitation of physical activity. Comfortable at rest, 
but less than ordinary physical activity causes symptoms 
of HF
Unable to carry on any physical activity without symptoms 
of HF, or symptoms of HF at rest
D Refractory HF requiring specialised interventions IV Unable to carry on any physical activity without symptoms 
of HF, or symptoms of HF at rest
ACCF = American College of Cardiology Foundation; AHA = American Heart Association; HF = Heart failure: NYHA = New York Heart Association.
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Perioperative triggers of acute cardiac 
decompensation
In the perioperative period, HF patients face numerous 
triggers of acute cardiac decompensation including 
hyper tension, tachyarrhythmias, anaemia, hypercoag-
ulability, inappropriate ®uid management, pain, surgi-
cal stress, pulmonary hypertension (PHT), pulmonary 
or fat emboli and myocardial ischaemia [19]. Cardiac 
 surgery may be complicated by coronary bypass 
 occlusion, intracoronary air embolism, paravalvular or 
 residual valvular regurgitation, PHT, tamponade, 
haemo- or pneumothorax. Patients with endstage or 
advanced HF who are symptomatic at rest despite max-
imal medical therapy (stage IV) present a unique chal-
lenge for perioperative management, and are at high 
risk for perioperative mortality (10–30%); however, 
their mortality drops to 6% when they are in a compen-
sated stage (I–II) [10]. If not an emergency, surgery 
should be postponed in patients with decompensated, 
new onset or untreated HF [13]. Anaesthetising patients 
with ongoing therapy for acute HF requires a good 
knowledge of the disease and its treatments, as well as 
possible haemodynamic consequences of anaesthesia 
[25]. An assessment of a patient’s prognosis linked to 
his or her cardiac disease can help to determine the role 
of interventions for noncardiac diseases, meaning that 
patients with a very poor cardiac prog nosis may not 
survive long enough to benet from some noncardiac 
procedures [26]. The optimal peri operative course of 
high-risk cardiovascular patients should be based on 
close cooperation between cardiologists, surgeons, an-
aesthesiologists and intensivists. 
Any patients with RVF or LVF poorly tolerate circula-
tory overload; overzealous ®uid infusion could ex-
plain some forms of iatrogenic perioperative HF. If LVF 
patients nicely tolerate the vasodilating eects of an-
aesthetics agents and LV unloading with mechanical 
ventilation, the most vulnerable time is the period of 
weaning from the ventilator and extubation. In con-
trast, RVF patients poorly tolerate the negative ino-
tropic eect of anaesthetic agents and the increase in 
right ventricular aerload resulting from mechanical 
ventilation; any signicant drop in systemic pressure 
(right ventricular perfusion) or hypoxic event (intraop-
erative mishaps or postoperative pulmonary compli-
cations) could precipitate or aggravate ongoing right 
ventricular decompensation. 
Since right and le ventricular failure represent dier-
ent entities with dierent management, they will be 
discussed separately.
Specic perioperative considerations 
of le ventricular failure 
Premedication
In the absence of evidence-based studies, similar 
 perioperative management can be recommended in 
patients with LVF with preserved ejection fraction as in 
patients with LVF and reduced ejection fraction. The 
perioperative management of LVF starts with the pre-
operative visit. The rst step will be to identify preex-
Table 2: Causes of left and right ventricular failure (modified from [71]).
Mechanism Left ventricular failure Right ventricular failure
Excessive pressure  
load
Aortic stenosis
Hypertrophic obstructive cardiomyopathy
Arterial hypertension
Primary or secondary pulmonary  hypertension 
HTPL/LTPL
Pulmonary stenosis
Some types of congenital heart disease  
(i.e., Fallot)
Excessive volume  
load
Aortic or mitral regurgitation
High-output states (thyrotoxicosis)
Some types of congenital heart disease (i.e., VSD)
Iatrogenic
Pulmonary or tricuspid regurgitation
ASD
Iatrogenic
LVAD
Primary myocardial  
disease
Ischaemic heart disease
Hypertrophic nonobstructive cardiomyopathy
Hypertrophic obstructive cardiomyopathy
Dilated cardiomyopathy
Cardiomyopathy of the elderly
Myocarditis
Metabolic heart disease
Endocrine heart disease
Ischemic heart disease
Hypertrophic obstructive  cardiomyopathy
Dilated cardiomyopathy
Arrhythmogenic cardiomyopathy
Myocarditis
Impaired ventricular  
filling
Tight mitral stenosis
Constrictive pericarditis
Restrictive cardiomyopathy
Tight tricuspid stenosis
Constrictive pericarditis
Restrictive cardiomyopathy
Tamponade
Some types of congenital heart disease  
(i.e., Ebstein anomaly)
ASD = atrial septal defect; HTPL = heart transplantation; LTPL = lung transplantation; LVAD = left ventricular assist device; VSD = ventricular septal 
defect.
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isting systolic or diastolic abnormalities of the le ven-
tricular function and establish the diagnosis of the 
underlying cardiac disease (table 2). Clinical signs of 
le ventricular dysfunction, although nonspecic, 
(tachy pnoea, orthopnoea, rales, legs oedema, hypoten-
sion, tachycardia, oliguria, cyanosis, mottling and 
somnolence), and the electrocardiogram (ECG; ar-
rhythmias, tachycardia, signs of old or recent myocar-
dial infarction, strain pattern, le bundle-branch 
block), chest X ray (cardiomegaly, pulmonary oedema), 
transthoracic echocardiography (TTE), coronary angio-
gram if relevant, as well as laboratory data (troponin, 
BNP or proNT-BNP, kidney and liver para meters, hae-
matology values) will all be studied carefully. TTE is 
the screening investigation of choice. Individualised 
premedication and anxiolytic therapy is then adminis-
tered, avoiding stress, but also respiratory depression 
and hypotension. Preoperative HF therapy other than 
diuretics (beta-blockers, angiotensin converting-en-
zyme inhibitors, angiotensin receptor blockers) should 
be further administered over the perioperative phase. 
When angiotensin converting-enzyme inhibitors and 
angiotensin receptor blockers are prescribed for sys-
tolic ventricular failure, the risk of hypotension during 
anaesthesia is much less than when they are pre-
scribed for systemic hypertension; in this latter case, 
their transient discontinuation 24 hours before sur-
gery should be considered [15].
Intraoperative prevention
Intraoperatively, the next step will be to prevent any 
worsening of le ventricular function. The haemody-
namic goals in the case of le ventricular failure are to 
optimise le ventricular preload and contractility, to 
reduce aerload, and to avoid tachycardia, bradycardia 
or arrhythmias. Simultaneously, hypoperfusion of ma-
jor organs and reduction of coronary blood ®ow must 
be prevented. Particular attention on avoiding over-
dose of drugs should be kept in mind, particularly dur-
ing induction, as the patient’s sensitivity is high and 
circulation time is slow. Frail patients maintain an ac-
ceptable cardiac output only within very restricted 
limits at rest, but have lost all physiological reserve in 
case of increased demand such as during surgery. 
Therefore, it is of the utmost importance to maintain 
rigorously a stable haemodynamic status, to immedi-
ately correct any signicant deviation, and to equili-
brate cardiac output with metabolic requirements. Ma-
jor surgery can be successfully undertaken in patients 
with a depressed haemodynamic condition as long as 
no intercurrent complication supervenes. Oxygen 
debt, acidosis and hypoperfusion intraoperatively will 
lead to multiple organ failure appearing later in the 
postoperative course. Fatal issue usually happens aer 
a few days of intensive care, which may leave the 
wrong impression that anaesthesia management is 
not involved in this dismal outlook.
A recent meta-analysis showed that goal-directed ther-
apy (GDT) in high-risk surgery is benecial in reducing 
cardiovascular events (odds ratio 0.54), irrespective of 
the choice of monitored physiological parameter or 
haemodynamic monitor in use [27]. The benet was 
most pronounced in patients receiving ®uid and ino-
trope therapy to achieve a supranormal oxygen deliv-
ery target, with the use of minimally invasive cardiac 
output monitoring. However, a Cochrane review found 
no dierences in the rate of arrhythmias, myocardial 
infarction, congestive HF or pulmonary oedema be-
tween patients treated with perioperative GDT and 
control patients [28]. These inconsistent results regard-
ing clinical outcomes may be explained by poor adher-
ence by clinicians to the protocol or the inappropriate-
ness of the proposed algorithm in selected high-risk 
patients. The current evidence does not support wide-
spread implementation of GDT to reduce mortality but 
does suggest that complications and duration of hospi-
tal stay are reduced [28]. Large randomised studies are 
needed to solve this question denitely. Until then, in-
dividualised haemodynamic goals should be dened, 
depending upon the patient’s characteristics and insti-
tutional preferences, considering optimisation of ve-
nous saturation (central or mixed), blood lactate, 
stroke volume index and/or cardiac index.
Monitoring
The choice of monitoring for these patients should be 
discussed. In addition to the standard ASA surveil-
lance, extended haemodynamic monitoring must be 
adapted to the LVF patient and to the type of surgery. 
An arterial catheter and a multilumen central catheter 
will be necessary in most cases. The current trans-
oesophageal echocardiography (TEE) guidelines rec-
ommend the use of TEE in noncardiac surgery if severe 
haemodynamic, pulmonary and neurological compro-
mises are anticipated, or in the case of life-threatening 
circulatory instability unresponsive to conventional 
interventions [9, 29]. It is recommended in any open-
heart surgery and may be considered for coronary 
 artery bypass surgery. The authors believe that TEE is 
mandatory in any perioperative case of LVF, except in 
the case of absolute contraindications. Details on the 
TEE assessment of le ventricular function can be 
found elsewhere [30, 31]. 
There is no convincing evidence for the use of a pulmo-
nary artery catheter (PAC) in perioperative patients 
during noncardiac surgery. In a case-control analysis, 
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the perioperative use of a PAC was associated with a 
higher incidence of postoperative HF and noncardiac 
events than in a matched control group [32], and a me-
ta-analysis of 13 randomised studies showed a null ef-
fect of PAC on outcome, when used in a random fash-
ion during major surgery among critically ill patients 
[33]. However, these negative results do not preclude 
the use of PAC in selected cases. The use of less invasive 
perioperative cardiac output monitoring techniques 
(PiCCO™, Oesophageal Doppler, Flow-Track™ Vigileo) 
could be associated with a reduction in length of stay 
and complications [34], but large randomised studies 
are still lacking [15]. It should be reminded that the im-
pact of a monitoring device on clinical outcome relies 
entirely on the interpretation of the data made by the 
physician and on the therapeutic algorithm implanted 
in the institution, but not on the technique itself.
Choice of anaesthesia
In the general population, the choice of the anaesthetic 
agent has been considered to be of little importance in 
terms of patient outcome, provided that vital func-
tions are adequately supported. In compromised pa-
tients, however, induction agents are best chosen 
among the substances with the least haemodynamic 
eects. Most volatile and intravenous anaesthetic 
agents reduce preload, aerload and contractility, and 
require proper management to ensure maintenance of 
organ ®ow and perfusion pressure. Induction agents 
may be classied by increasing order of negative ino-
tropic action as follows: etomidate, midazolam, propo-
fol, ketamine, and thiopental. The key conditions for a 
stable induction are: a reduction of the dose according 
to the degree of ventricular dysfunction, and a slow-
down in the rate of drug administration, completing 
very progressively the dose required for intubation. 
Opioids have no known adverse eects on the le ven-
tricular function. In patients suering from ischae-
mia-induced ventricular failure, use of halogenated 
gases may be advised because of their preconditioning 
eect [35]. In coronary artery bypass gra (CABG) sur-
gery, they tend to improve myocardial performance re-
covery [36]; whether this can be extrapolated to non-
cardiac surgery is still debated. Intermittent positive 
pressure ventilation (IPPV) is well tolerated in le ven-
tricular failure because the increase in intrathoracic 
pressure corresponds to a decrease in le ventricular 
aerload. If a neuraxial technique is chosen, the local 
anaesthetic agent should be introduced slowly to avoid 
systemic vasodilation. When the blockade reaches the 
fourth thoracic dermatome, a reduction in cardiac 
sympathetic tone may occur with a decrease in myo-
cardial contractility, heart rate, and change in loading 
conditions. The  ESC/ESA guidelines have estimated, 
however, that neuraxial anaesthesia and analgesia 
may be considered for the management of patients 
with cardiovascular risk factors or diseases [15]. 
Perioperative LVF management
Early identication of LVF and the underlying cardiac 
disease, as well as prompt and aggressive manage-
ment, decrease postoperative morbidity and mor tality. 
The search for reversible conditions is essential: myo-
cardial ischaemia or infarction, acute valvular dys-
function, le ventricular tract obstruction with sys-
tolic anterior motion of the mitral valve, septic shock, 
Table 3: Management of perioperative heart failure.
Left ventricular failure Right ventricular failure
Avoidance of drug-induced myocardial depression Avoidance of drug-induced myocardial depression
Preservation of ventricular interaction
Optimisation of preload Optimisation of preload
Maintenance of SR and A–V synchrony
Heart rate control
Maintenance of SR and A–V synchrony
Heart rate control
Reduction of left ventricular afterload Avoidance of PHT exacerbation: hypoxemia, hypercarbia, 
hypothermia, acidosis, stress and pain
Optimization of ventilator settings
Maintenance of adequate systemic perfusion pressure  
for organ perfusion
Maintenance of systemic perfusion pressure while  
minimising right ventricular dilatation
Avoidance of nephrotoxic and hepatotoxic drugs Avoidance of nephrotoxic and hepatotoxic drugs
Minimisation of blood transfusion, especially of old blood
Tailoring of therapy to the specific aetiology of the LVF Tailoring of therapy to the specific aetiology of the RVF 
Reduction of right ventricular afterload, preferentially  
with inhalative therapy
Inotropic support Inotropic support
Mechanical assist devices Mechanical assist devices
A–V synchrony = atrioventricular synchrony; LVF = left ventricular failure; RVF = right ventricular failure; PHT = pulmonary hypertension.
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aortic dissection type I or postcardiotomy in the case 
of cardiac surgery must be treated appropriately. Re-
suscitation measures must be undertaken immedi-
ately. Similarly to sepsis therapy, the concept of the 
“golden hours” for acute HF management is essential 
[19]. Oxygenation and ventilation should be immedi-
ately maximised and acid-base as well as electrolyte 
abnormalities should be corrected. Optimisation of 
preload, aerload and contractility (table 3), ideally un-
der echocardiographic monitoring, and control of the 
heart rate and rhythm should stabilise the le ventri-
cle. Positive inotropic agents must be used with cau-
tion, with carefull consideration of their risk–benet 
ratio; several studies indicate an association between 
prescription of inotropes and poor clinical outcome 
[37]. It remains of great use in patients with acute sys-
tolic dysfunction and low cardiac output, and evidence 
of systemic hypoperfusion or congestion. The dosage 
should be kept as low as possible and the possibility of 
weaning should be regularly assessed (table 4). Until 
now, no catecholamines have been shown to improve 
outcome of patients, except levosimendan [38, 39]. In a 
recent large meta-analysis considering 45 randomised 
controlled trials and analysing 5 480 patients, levosim-
endan was shown to reduce mortality of adult patients 
in cardiology and cardiac surgery settings [40]. In a 
consensus of experts, levosimendan was included 
among eight nonsurgical ancillary drugs, techniques 
or strategies that might decrease mortality in cardiac 
surgery [41]. It has the great advantage of acting as both 
a positive inotrope and an aerload reduction agent, 
without increasing myocardial oxygen consumption. 
If LVF persists, mechanical assistance should be started 
as soon as possible and preferentially before organ dys-
function. Intra-aortic balloon counterpulsation (IABP) 
improves coronary perfusion through augmentation 
of diastolic pressure, decreases aerload and, conse-
quently, reduces myocardial oxygen consumption and 
increases cardiac output. It has been the most widely 
used mechanical circulatory support device for nearly 
ve decades, particularly during and aer cardiac sur-
gery. Following the results of the rst large ran-
domised, open-label trial on the use of IABP in acute 
myocardial infarction complicated by cardiogenic 
shock (IABP-SHOCK II), the indications for IABP have 
been greatly restricted [42, 43]. In the current guide-
lines, IABP is indicated only in cardiogenic shock com-
plicating myocardial infarction [15]. The use of IABP in 
noncardiac surgery is founded on case reports and 
small case series [44, 45], with good results in the acute 
perioperative time. In cases of refractory low cardiac 
output syndrome, extracorporeal life support (ECLS) 
might become an option. It should be inserted before 
irreversible organ dysfunction develops, as a bridge to 
decision, to recovery, to ventricular assist device 
(LVAD) or to transplantation.
The early postoperative care of LVF patients should be 
conducted in a high-acuity nursing environment, with 
invasive monitoring and requisite assessment of car-
diac biomarkers (e.g., troponin and brain natriuret ic 
peptides) [7]. Recent meta-analyses demonstrated that 
increased postoperative troponin and BNP concentra-
tions aer noncardiac surgery were associated with a 
signicantly increased risk of mortality [15, 46, 47]. Pre-
operatively and postoperatively, patients who could 
most benet from BNP or troponin measurements are 
those with METs ≤4 or with a revised cardiac risk index 
value >1 for vascular surgery and >2 for nonvascular 
surgery [15].
Diastolic dysfunction and failure are initially charac-
terised by a maintained cardiac output, but by restric-
tive lling  conditions (lack of relaxation, sti ven-
tricle). Elevated lling pressures, intolerance to 
tachycardia or bradycardia, and extreme dependence 
of stroke volume from preload (intolerance to hypovo-
laemia, large variations of arterial pressure with posi-
Table 4: Dose-related haemodynamic effects of intravenous inotropic agents in heart failure (modified from [2, 72]).
Dose mcg/kg Dose mcg/kg/min Effects Adverse effects
Inotropic agent Bolus Infusion CO HR SVR PVR
Dobutamine N/A 2.5 to 5
5 to 20
↑
↑
↑
↑
↓
↔
 ↔
 ↔
↑/↓ BP, T, HA, N, F, hyper-
sensitivity, O2myoc↑
Adrenaline N/A to 0.05
0.05 to 0.1
>0.1
↑ ↑
↑↔
↑↔↓
↑
↑ ↑
↑ ↑
↑
↑ ↑
↑ ↑ ↑
↑
↑ ↑
↑ ↑
T, A, F, lactate↑
Glyc↑, O2myoc↑↑
Milrinone N/R 0.125 to 0.175 ↑ ↑ ↑ ↓ ↓ A, T, ↓BP, O2myoc↑↔
Levosimendan N/R 0.05 to 0.2 ↑ ↑ ↑↔ ↓↓ ↓ T, A, HA, ↓BP, hypoK, 
O2myoc↔
A = arrhythmias; BP = blood pressure; CO = cardiac output; F = fever; Glyc = glycaemia; HA = headache; HR = heart rate; hypoK = hypokalaemia;  
N/A = not applicable; N = nausea; N/R = not recommended; O2myoc = myocardial O2 consumption; PVR = pulmonary vascular resistance;  
SVR = systemic vascular resistance; T = tachycardia.
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tive pressure ventilation) dene their haemodynamic 
behaviour. Dia stolic function is best evaluated with 
echocardiography. Unfortunately, there are no e-
cient means to improve diastolic function [48].
Specic perioperative considerations 
of right ventricular failure
The anaesthesiologist will be confronted with patients 
with right venticular failure in various circumstances 
(tables 2 and 5):
– In noncardiac surgery, perioperative right ventricu-
lar failure is most oen, although not exclusively, 
secondary to acute PHT; a normal right ventricle 
can cope for only 1–2 hours with a mean positive air-
way pressure of ≥40 mm Hg [49].
– In cardiac surgery, right ventricular failure may be 
secondary to acute PHT, but also frequently to vol-
ume overload, myocardial ischaemia, preexisting 
right ventricular dysfunction or arrhythmias. 
Among cardiac surgery patients, those undergoing 
cardiac transplantation or LVAD implantation are at 
higher risk.
– Grown-up congenital heart disease (GUCH) patients, 
for cardiac or noncardiac surgery.
Premedication
The perioperative management of right ventricular 
failure, like the management of le ventricular failure, 
consists of several successive steps, starting with a pre-
operative visit. The rst step is to identify preexisting 
abnormalities of the right ventricular function and of 
the pulmonary vasculature, knowing that periopera-
tive risk factors for right ventricular decompensation 
include a preexisting right ventricular dysfunction, or 
severe PHT without right ventricular dysfunction. A 
thorough history and clinical examination is required. 
Clinical signs of right ventricular dysfunction, al-
though nonspecic (dys pnoea, hypotension, right up-
per quadrant discomfort, ascites, jugular vein disten-
sion), and ECG (sinus tachycardia, T-wave inversion in 
III and aVF or V1 to V4, right bundle-branch block, right-
ward axis), chest X ray (pulmonary artery, right atrium 
and right ventricular dilation), transthoracic echocardi-
ography (TTE), right heart catheterisation in cases of 
moderate to severe right ventricular  dysfunction com-
bined with severe PHT [50] and laboratory values, must 
all be studied carefully. TTE is the screening investiga-
tion of choice. Individualised premedication and anxio-
lytic therapy is then administered, avoiding stress, but 
also respiratory depression with the risk of secondary 
PHT. Preoperative chronic PHT therapy should be fur-
ther administered over the perioperative period.
Intraoperative prevention
Intraoperatively, the next step will be to prevent any 
aggravation of possible pre-existing RV dysfunction. 
In this view, any increase in pulmonary vascular 
 resistance (PVR) and right ventricular myocardial is-
chaemia, which exacerbate each other, should be 
avoided. The haemo dynamic goals are to maintain 
right ventricular preload and contractility, minimising 
the PVR and avoiding right ventricular coronary hypo-
perfusion.
Monitoring
As for the patients in le ventricular failure, an arterial 
catheter and a multilumen central venous catheter 
will be useful, particularly in the case of IPPV. Intraop-
erative TEE is mandatory in all patients with RVF, ex-
cept in the case of absolute contraindication [51]. Detail 
on the TEE assessment of right ventricular function 
can be found in previous publications [52–54] as well as 
on the ASE website (www.asecho.org).
A PAC may be indicated in case of severe PHT and RVF, 
but should be used with caution considering the risk 
for arrhythmias and catheter-induced pulmonary ar-
tery rupture [55]. The measurement of cardiac output 
may be altered in the presence of tricuspid regurgita-
tion. The use of continuous right ventricular pressure 
waveform monitoring might be helpful, as described 
by Denault et al. [16] (g. 1). In cases of right ventricular 
dysfunction, a progressive change in the diastolic pres-
sure slope from horizontal to obliquely ascending will 
Table 5: Occurrences of acute perioperative right ventricular failure.
Noncardiac surgery
PHT: hypoxia, hypoventilation, atelectasis, high ventilation pressures, acute pulmonary 
embolism (orthopaedic surgery)
Myocardial ischaemia: coronary artery disease
Elevated LAP: mitral valve disease, systolic or diastolic LVF
LVAD 
Lung transplantation
GUCH
Cardiac surgery
Myocardial ischaemia or infarction
Inadequate myocardial protection, intracoronary air  embolism
RV diastolic dysfunction associated with abnormal  interventricular septal motion
PHT: CPB, protamine reaction, acute on chronic PHT
LVAD
HTPL 
GUCH
CPB = cardio-pulmonary bypass; GUCH = grown-up congenital heart disease; HTPL = heart transplan-
tation; LAP = left arterial pressure; LVAD = left ventricular assist device; PHT = pulmonary hyperten-
sion; RVF = right ventricular failure.
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be observed. As right ventricular function deterio-
rates, the slope will change to a square root shape, and 
nally right ventricular and pulmonary diastolic pres-
sures will equalise [16]. Combining right ventricular 
pressure waveform and TEE monitoring allows rapid 
determination of the cause of right ventricular systolic 
and diastolic dysfunction.
Choice of anaesthesia
The choice of anaesthetic is equally relevant in the pre-
vention of RVF. The depth of anaesthesia and postoper-
ative analgesia should be sucient to avoid large sym-
pathetic haemodynamic responses to pain and 
surgery. Volatile anaesthetics may all worsen right 
ventricular dysfunction by reducing preload, aerload 
and contractility. The PVR is increased by both des®u-
rane and nitrous oxide [56, 57]. Ketamine seems to in-
crease PVR in adults but not in children [58, 59]. 
 Although the poten tial deleterious eect on PVR re-
mains a concern, it must be balanced against the po-
tential benets of  combined analgesia and hypnosis 
and its absence of signicant myocardial depression 
and vasodilation [60]. Etomidate has been advocated 
as the induction agent of choice although there is no 
comparative data [61, 62]. Opioids have no known ad-
verse eects on the right ventricular function. If a neu-
raxial technique is chosen, a local anaesthetic agent 
should be introduced slowly to avoid inconsiderate 
systemic vasodilation. 
Perioperative RVF management
The third step consists of early identication of RVF. 
The functional state of the right ventricle cannot be de-
termined from the severity of PHT alone. In a patient 
with known PHT developing RVF, the PAP will pseudo- 
normalise as right ventricular function fails. In other 
words, while a falling PAP may be due to a reduction in 
PVR or le atrial pressure (LAP), it might also be a sign 
of a failing right ventricle that cannot build up the 
pressure any more. Conversely, an increase in cardiac 
output in the face of a high, relatively xed PVR will in-
crease the PAP. In cases of progressive RVF, PAP may ap-
pear normal but right atrial pressure (RAP) will be ele-
vated. Both systemic and pulmonary artery pressures 
will be reduced to a similar degree; the ratio of sys-
temic to pulmonary mean arterial pressures may bet-
ter re®ect the severity of PHT. In cardiac surgery, this 
ratio has been shown to be a better predictor of postop-
erative complications than the absolute values [63]. A 
search for possible underlying reversible conditions is 
essential: pulmonary embolism, lung  infection, bron-
chial asthma, COPD, ventilation/perfusion mismatch, 
valvulopathy, myocardial ischaemia, intracardiac 
shunt and le ventricular diastolic or systolic dysfunc-
tion can all contribute to RVF.
Finally, in presence of progressive RVF, standard ther-
apy is initiated (table 3), keeping in mind that one of 
the main goals of management is the maintenance of 
the ventricular interaction. Right ventricular function 
is signicantly reduced if the septum is dysfunctional; 
the maximum right ventricular developed pressure is 
reduced by 30% when the septum is inactivated [64]. 
Conditions that reduce the le ventricular systolic 
pressure or increase the right ventricular systolic pres-
sure reverse the trans-septal gradient and lead to fur-
ther RVF [65, 66]. Although the right ventricle is highly 
preload-dependent, overlling can cause right ven-
tricular  dilation and secondary tricuspid regurgitation 
with a resulting increase in right ventricular wall 
stress, decrease in le ventricular compliance and pro-
gressive reduction of cardiac output, leading to further 
right ventricular dilation (g. 2). Preload is optimised, 
observing the eect of a volume tolerance test on cen-
tral venous pressure, PAP and right ventricular lling 
(TEE/TTE). However, pulse pressure variation cannot 
be used for ®uid assessment in patients with RVF, as 
pulsus paradoxus might result from RVF and ventricu-
lar interdependence [67, 68]. Sinus rhythm is main-
tained as well as a heart rate of at least 90/min. The 
right ventricular aerload is decreased, initially using 
Figure 1: Zoomed right ventricular pressure (PRV) and pulmonary arterial pressure (PPA) 
with their corresponding Doppler  hepatic venous flow (HVF) before (a, b) and after 
 cardio-pulmonary bypass. Note the change in the diastolic slope of the PRV waveform 
and the corresponding change in the systolic (S) to diastolic (D) ratio of the HVF.  
From: Denault AY, Haddad F, Jacobsohn E, Deschamps A. Perioperative right ventricular 
 dysfunction. Current opinion in anaesthesiology. 2013;26(1):71–81, reprinted with 
 permission. 
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100% FiO2, mild hyperventilation, alkalinisation, and 
adaptation of ventilation settings: the relationship be-
tween tidal volume and PVR has a unique “U” shape, 
PVR being minimal at functional residual capacity and 
maximal in the event of hypoventilation or hyperin-
®ation [52, 53]. Any sympathetic stimulation such as 
stress, pain, anxiety, hypothermia and shivering is 
suppressed, and anaesthetics potentially associated 
with augmentation of PVR are avoided. If these diverse 
measures do not allow a stabilisation of the right ven-
tricular function, pulmonary vasodilatation is then 
started, preferentially using inhalational substances 
such as nitric  oxide (NO), iloprost or milrinone, to 
avoid systemic vasodilation. Because of their dierent 
modes of action, combination of inhalational vasodila-
tors might be synergistic [50, 62]. Keep in mind that the 
key haemo dynamic sign of a therapeutic response to 
inhaled pulmonary vasodilators is not a reduction in 
pulmonary artery pressure but a decrease in CVP and 
an increase in cardiac output [62]. Considering further 
ventricular interdependence [69, 70] as well as the cor-
onary perfusion of the right ventricular myo cardium, 
the systemic arterial pressure is maintained  elevated 
to avoid right ventricular myocardial ischaemia, using 
vasopressors as needed (noradrenaline, vasopressin). 
The benet of systemic vasoconstriction has to be bal-
anced with the risk of pulmonary vasoconstriction; 
fortunately, the pulmonary arterial tree has fewer 
alpha- receptors than the systemic arteries and is de-
void of receptors for vasopressin [50]. Finally, inotropic 
agents are deployed as needed: dobutamine, adrena-
line, phosphodiesterases III inhibitors (milrinone) or 
levosi mendan have all been shown to be eective in 
case of acute RVF. However, as levosimendan and mil-
rinone both produce systemic vasodilation, vaso-
pressors may need to be coadministered to prevent 
 reduced right coronary blood ®ow [62]. Increased le 
ventricular contractility can also result in increased 
right ventricular systolic function through ventricular 
interdependence. 
In cases of persistent refractory RVF, mechanical sup-
port with a ventricular assist device should be initi-
ated, preferentially before the appearance of irrevers-
ible organ dysfunction.
Conclusion
In conclusion, perioperative heart failure is the result 
of inadequate contractility, arrhythmia, volume or 
pressure overload and is associated with worse out-
comes in noncardiac and cardiac surgery. Particular 
care has to be taken of the right ventricle. Prevention, 
diagnosis and therapy are dicult tasks for the team 
managing the patient, including anaesthesiologists, 
cardiologists, surgeons and intensivists. The adequacy 
of the perioperative management determines the late 
postoperative outcome.
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Figure 2: Right ventricular dysfunction after tricuspid valve replacement 
with obvious septum shift toward the left ventricle.
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